menu
    • menu
    [{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"Inventiva Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Lanifibranor","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Sino Biopharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"},{"orgOrder":0,"company":"Sino Biopharmaceutical","sponsor":"LaNova Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Series C Financing","leadProduct":"Apatinib","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Sino Biopharmaceutical","amount2":0.040000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Sino Biopharmaceutical \/ Sino Biopharmaceutical","highestDevelopmentStatusID":"14","companyTruncated":"Sino Biopharmaceutical \/ Sino Biopharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Sino Biopharmaceutical

    Menu

    Sino Biopharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LM-302,Rivoceranib,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : LaNova Medicines

                            Deal Size : $42.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            LaNova Initiates Phase 1 for LM-299 Anti-PD-1/VEGF Antibody and $42M Financing

                            Details : The financing is intended to support the clinical development of LM-302, an anti-CLDN 18.2 ADC, which is currently in late-stage clinical trials in China for the treatment of gastric cancers.

                            Brand Name : LM-302

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            October 18, 2024

                            Lead Product(s) : LM-302,Rivoceranib,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : LaNova Medicines

                            Deal Size : $42.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Sino Biopharmaceutical

                            Hong Kong arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inventiva Announces that its Partner Sino Biopharm Received IND Approval from the NMPA to initiate Clinical Tr...

                            Details : IVA337 (Lanifibranor), is an orally-available small molecule which induces anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three PPAR isoforms, regulating gene expression.

                            Brand Name : IVA337

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 25, 2023

                            Lead Product(s) : Lanifibranor

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : Inventiva Pharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth